GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » PE Ratio without NRI

Translate Bio (Translate Bio) PE Ratio without NRI : 73.83 (As of Apr. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-04-27), Translate Bio's share price is $37.36. Translate Bio's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $0.51. Therefore, Translate Bio's PE Ratio without NRI for today is 73.83.

During the past 5 years, Translate Bio's highest PE Ratio without NRI was 74.64. The lowest was 36.28. And the median was 58.80.

Translate Bio's EPS without NRI for the three months ended in Jun. 2021 was $0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $0.51.

As of today (2024-04-27), Translate Bio's share price is $37.36. Translate Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.51. Therefore, Translate Bio's PE Ratio for today is 73.83.

Warning Sign:

Translate Bio Inc stock PE Ratio (=73.83) is close to 1-year high of 74.64

During the past years, Translate Bio's highest PE Ratio was 74.64. The lowest was 36.28. And the median was 58.80.

Translate Bio's EPS (Diluted) for the three months ended in Jun. 2021 was $0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.51.

Translate Bio's EPS (Basic) for the three months ended in Jun. 2021 was $0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.55.


Translate Bio PE Ratio without NRI Historical Data

The historical data trend for Translate Bio's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio PE Ratio without NRI Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
PE Ratio without NRI
N/A N/A At Loss At Loss At Loss

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 54.43

Competitive Comparison of Translate Bio's PE Ratio without NRI

For the Biotechnology subindustry, Translate Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Translate Bio's PE Ratio without NRI falls into.



Translate Bio PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Translate Bio's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=37.36/0.506
=73.83

Translate Bio's Share Price of today is $37.36.
Translate Bio's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Translate Bio  (NAS:TBIO) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Translate Bio PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Translate Bio's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109